Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EDIT 
Editas Medicine Inc (EDIT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: EDIT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4
1 Year Target Price $4
| 4 | Strong Buy |
| 1 | Buy |
| 8 | Hold |
| 2 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.29% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 241.89M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 15 | Beta 2.16 | 52 Weeks Range 0.91 - 4.12 | Updated Date 09/15/2025 |
52 Weeks Range 0.91 - 4.12 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -711.63% |
Management Effectiveness
Return on Assets (TTM) -33.76% | Return on Equity (TTM) -188.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 84519241 | Price to Sales(TTM) 6.22 |
Enterprise Value 84519241 | Price to Sales(TTM) 6.22 | ||
Enterprise Value to Revenue 2.17 | Enterprise Value to EBITDA -1.36 | Shares Outstanding 89920200 | Shares Floating 89572173 |
Shares Outstanding 89920200 | Shares Floating 89572173 | ||
Percent Insiders 0.3 | Percent Institutions 49.2 |
Upturn AI SWOT
Editas Medicine Inc
Company Overview
History and Background
Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. It's a clinical-stage genome editing company focused on developing transformative genomic medicines for a broad range of serious diseases. It has gone through preclinical and clinical stages with milestones achieved in its EDIT-101 program.
Core Business Areas
- Therapeutic Development: Focuses on developing and commercializing CRISPR-based genome editing therapeutics across various disease areas including ocular, oncology, and other genetic diseases.
- Technology Platform: Advancing their CRISPR technology platform, including novel CRISPR enzymes and delivery methods, to improve the safety and efficacy of gene editing.
- Research and Development: Conducting research and development activities to discover new targets and develop innovative gene editing therapies.
Leadership and Structure
The leadership team consists of key executives responsible for research, clinical development, and corporate strategy. The organizational structure involves research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- EDIT-101: An experimental AAV5-delivered CRISPR medicine being developed for the treatment of Leber congenital amaurosis 10 (LCA10), a form of inherited blindness. Currently in clinical trials (Phase 1/2). Competitors include companies developing gene therapies for inherited retinal diseases. Revenue is currently limited to partnership/licensing agreements until EDIT-101 is approved. Market share is currently 0 as it's not approved for sale yet.
- EDIT-301: An experimental gene editing medicine in Phase 1/2 trials for severe sickle cell disease. EDIT-301 utilizes Editas' proprietary AsCas12a enzyme. Competitors include Vertex Pharmaceuticals (CRSP) and Bluebird Bio (BLUE) with their approved and experimental gene therapies for sickle cell disease. Market share is currently 0 as it's not approved for sale yet.
Market Dynamics
Industry Overview
The gene editing industry is rapidly evolving, driven by technological advancements and increasing applications in healthcare. It is characterized by high R&D investments, regulatory scrutiny, and intense competition.
Positioning
Editas Medicine is positioned as a leading player in the CRISPR gene editing space, focusing on developing therapies for inherited diseases. Its competitive advantage lies in its proprietary CRISPR technology and clinical programs.
Total Addressable Market (TAM)
The TAM for gene editing therapies is estimated to reach billions of dollars annually. Editas is positioned to capture a significant share with successful clinical trials and commercialization.
Upturn SWOT Analysis
Strengths
- Pioneering CRISPR technology platform
- Strong intellectual property portfolio
- Experienced leadership team
- Clinical-stage programs with promising results
- Strategic partnerships with leading institutions
Weaknesses
- High cash burn rate
- Dependence on clinical trial success
- Regulatory uncertainties
- Limited commercial infrastructure
- Relatively small market capitalization compared to competitors
Opportunities
- Expanding therapeutic applications of CRISPR
- Partnering with pharmaceutical companies for co-development
- Advancements in gene delivery technologies
- Receiving regulatory approvals for lead candidates
- Addressing unmet medical needs in genetic diseases
Threats
- Competition from other gene editing companies
- Adverse clinical trial outcomes
- Regulatory delays or rejection
- Ethical concerns surrounding gene editing
- Patent disputes
Competitors and Market Share
Key Competitors
- CRSP
- BEAM
- NTLA
- BLUE
Competitive Landscape
Editas Medicine is a key player in the gene editing field but faces stiff competition from larger and more established companies. They have a strong technology platform but must demonstrate clinical success to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on the specific period being considered. Financial records should be consulted for accuracy.
Future Projections: Future projections depend on analyst estimates and market conditions. These can be obtained from financial news providers.
Recent Initiatives: Recent initiatives include advancing clinical trials of EDIT-101 and EDIT-301 and expanding partnerships.
Summary
Editas Medicine is a pioneering CRISPR gene editing company with promising clinical programs, particularly EDIT-101 and EDIT-301. Their strength lies in their innovative technology, but they face challenges related to funding, clinical trial outcomes, and competition. The company needs to successfully navigate the regulatory landscape and achieve clinical milestones to capitalize on the growing gene editing market. Managing cash burn and securing additional funding will also be important for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Analyst reports, Press releases
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share percentages are approximations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Editas Medicine Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2016-02-03 | President, CEO & Director Dr. Gilmore O'Neill M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 246 | Website https://www.editasmedicine.com |
Full time employees 246 | Website https://www.editasmedicine.com | ||
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.